Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Fatal reversible cerebral vasoconstriction syndrome.

Kunchok A, Castley HC, Aldous L, Hawke SH, Torzillo E, Parker GD, Halmagyi GM.

J Neurol Sci. 2018 Feb 15;385:146-150. doi: 10.1016/j.jns.2017.12.009. Epub 2017 Dec 8.

PMID:
29406896
2.

Exosomal microRNA signatures in multiple sclerosis reflect disease status.

Ebrahimkhani S, Vafaee F, Young PE, Hur SSJ, Hawke S, Devenney E, Beadnall H, Barnett MH, Suter CM, Buckland ME.

Sci Rep. 2017 Oct 30;7(1):14293. doi: 10.1038/s41598-017-14301-3.

3.

Incidence and prevalence of NMOSD in Australia and New Zealand.

Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L, Silvestrini RA, Bundell CS, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brown M, Brownlee WJ, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Killpatrick T, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonell R, Mason DF, McCombe PA, Pender MP, Pereira JA, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Wilson RJ, Vincent A, Broadley SA.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):632-638. doi: 10.1136/jnnp-2016-314839. Epub 2017 May 26.

4.

Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients.

Zinger A, Latham SL, Combes V, Byrne S, Barnett MH, Hawke S, Grau GE.

Mult Scler. 2016 Dec;22(14):1883-1887. Epub 2016 Mar 1.

PMID:
26931477
5.

Differential Toxicity of Antibodies to the Prion Protein.

Reimann RR, Sonati T, Hornemann S, Herrmann US, Arand M, Hawke S, Aguzzi A.

PLoS Pathog. 2016 Jan 28;12(1):e1005401. doi: 10.1371/journal.ppat.1005401. eCollection 2016 Jan.

6.

Autosomal dominant congenital spinal muscular atrophy: a true form of spinal muscular atrophy caused by early loss of anterior horn cells.

Oates EC, Reddel S, Rodriguez ML, Gandolfo LC, Bahlo M, Hawke SH, Lamandé SR, Clarke NF, North KN.

Brain. 2012 Jun;135(Pt 6):1714-23. doi: 10.1093/brain/aws108.

PMID:
22628388
7.

Epitope-specific anti-prion antibodies upregulate apolipoprotein E and disrupt membrane cholesterol homeostasis.

Tayebi M, David M, Bate C, Jones D, Taylor W, Morton R, Pollard J, Hawke S.

J Gen Virol. 2010 Dec;91(Pt 12):3105-15. doi: 10.1099/vir.0.023838-0. Epub 2010 Aug 25.

PMID:
20797970
8.

Unswitched immunoglobulin M response prolongs mouse survival in prion disease.

Tayebi M, Collinge J, Hawke S.

J Gen Virol. 2009 Mar;90(Pt 3):777-82. doi: 10.1099/vir.0.005041-0.

PMID:
19218226
9.

Beta-PrP form of human prion protein stimulates production of monoclonal antibodies to epitope 91-110 that recognise native PrPSc.

Khalili-Shirazi A, Kaisar M, Mallinson G, Jones S, Bhelt D, Fraser C, Clarke AR, Hawke SH, Jackson GS, Collinge J.

Biochim Biophys Acta. 2007 Nov;1774(11):1438-50. Epub 2007 Sep 6.

PMID:
17936697
10.

A role for B lymphocytes in anti-infective prion therapies?

Tayebi M, Bate C, Hawke S, Williams A.

Expert Rev Anti Infect Ther. 2007 Aug;5(4):631-8. Review.

PMID:
17678426
11.

Antibody-mediated neuronal apoptosis: therapeutic implications for prion diseases.

Tayebi M, Hawke S.

Immunol Lett. 2006 Jun 15;105(2):123-6. Epub 2006 Mar 29. Review.

PMID:
16621033
12.

PrP glycoforms are associated in a strain-specific ratio in native PrPSc.

Khalili-Shirazi A, Summers L, Linehan J, Mallinson G, Anstee D, Hawke S, Jackson GS, Collinge J.

J Gen Virol. 2005 Sep;86(Pt 9):2635-44.

PMID:
16099923
13.

Protein conformation significantly influences immune responses to prion protein.

Khalili-Shirazi A, Quaratino S, Londei M, Summers L, Tayebi M, Clarke AR, Hawke SH, Jackson GS, Collinge J.

J Immunol. 2005 Mar 15;174(6):3256-63.

14.

Disease-associated prion protein elicits immunoglobulin M responses in vivo.

Tayebi M, Enever P, Sattar Z, Collinge J, Hawke S.

Mol Med. 2004 Jul-Dec;10(7-12):104-11.

15.

Distribution and quantification of human herpesvirus 6 in multiple sclerosis and control brains.

Tuke PW, Hawke S, Griffiths PD, Clark DA.

Mult Scler. 2004 Aug;10(4):355-9.

PMID:
15327029
16.

PrPSc binding antibodies are potent inhibitors of prion replication in cell lines.

Beringue V, Vilette D, Mallinson G, Archer F, Kaisar M, Tayebi M, Jackson GS, Clarke AR, Laude H, Collinge J, Hawke S.

J Biol Chem. 2004 Sep 17;279(38):39671-6. Epub 2004 May 7.

17.

Immunotherapy as a therapeutic treatment for neurodegenerative disorders.

White AR, Hawke SH.

J Neurochem. 2003 Nov;87(4):801-8. Review.

18.

Regional heterogeneity of cellular prion protein isoforms in the mouse brain.

Beringue V, Mallinson G, Kaisar M, Tayebi M, Sattar Z, Jackson G, Anstee D, Collinge J, Hawke S.

Brain. 2003 Sep;126(Pt 9):2065-73. Epub 2003 Jun 23.

PMID:
12821516
19.

Monoclonal antibodies inhibit prion replication and delay the development of prion disease.

White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S, Anstee D, Collinge J, Hawke S.

Nature. 2003 Mar 6;422(6927):80-3.

PMID:
12621436
20.

Sjögren's syndrome-associated myelopathy: response to immunosuppressive treatment.

Vincent TL, Richardson MP, Mackworth-Young CG, Hawke SH, Venables PJ.

Am J Med. 2003 Feb 1;114(2):145-8. No abstract available.

PMID:
12586236
21.

Uncoupling of virus-induced inflammation and anti-viral immunity in the brain parenchyma.

Stevenson PG, Austyn JM, Hawke S.

J Gen Virol. 2002 Jul;83(Pt 7):1735-43.

PMID:
12075093
22.

Dominant negative guard cell K+ channel mutants reduce inward-rectifying K+ currents and light-induced stomatal opening in arabidopsis.

Kwak JM, Murata Y, Baizabal-Aguirre VM, Merrill J, Wang M, Kemper A, Hawke SD, Tallman G, Schroeder JI.

Plant Physiol. 2001 Oct;127(2):473-85.

23.

Alteration of stimulus-specific guard cell calcium oscillations and stomatal closing in Arabidopsis det3 mutant.

Allen GJ, Chu SP, Schumacher K, Shimazaki CT, Vafeados D, Kemper A, Hawke SD, Tallman G, Tsien RY, Harper JF, Chory J, Schroeder JI.

Science. 2000 Sep 29;289(5488):2338-42.

24.

Distant interactions between dimorphisms in HLA-DR4 radically affect recognition of defined peptides by a specific T cell clone.

Matsuo H, Corlett L, Hawke S, Nicolle M, Driscoll P, Deshpande S, Spack E, Willcox N.

Int Immunol. 1999 May;11(5):835-43.

PMID:
10330288
25.

Cross-restriction of a T cell clone to HLA-DR alleles associated with rheumatoid arthritis: clues to arthritogenic peptide motifs.

Hawke S, Matsuo H, Nicolle M, Wordsworth P, Corlett L, Spack E, Deshpande S, Driscoll PC, Willcox N.

Arthritis Rheum. 1999 May;42(5):1040-50.

26.

B lymphocytes in prion neuroinvasion: central or peripheral players?

Collinge J, Hawke S.

Nat Med. 1998 Dec;4(12):1369-70. No abstract available.

PMID:
9846572
27.

T-cell receptor immunotherapy in multiple sclerosis.

Hawke S.

Brain. 1998 Aug;121 ( Pt 8):1391-3. Review. No abstract available.

PMID:
9712002
28.

Long-term persistence of activated cytotoxic T lymphocytes after viral infection of the central nervous system.

Hawke S, Stevenson PG, Freeman S, Bangham CR.

J Exp Med. 1998 May 18;187(10):1575-82.

29.

Recruitment, activation and proliferation of CD8+ memory T cells in an immunoprivileged site.

Stevenson PG, Bangham CR, Hawke S.

Eur J Immunol. 1997 Dec;27(12):3259-68.

PMID:
9464814
30.

Too soon to market.

Dent TH, Hawke S.

BMJ. 1997 Nov 15;315(7118):1248-9. No abstract available.

31.

Virus dissemination through the brain parenchyma without immunologic control.

Stevenson PG, Freeman S, Bangham CR, Hawke S.

J Immunol. 1997 Aug 15;159(4):1876-84.

PMID:
9257852
32.

Protection against influenza virus encephalitis by adoptive lymphocyte transfer.

Stevenson PG, Hawke S, Bangham CR.

Virology. 1997 May 26;232(1):158-66.

33.

The immunogenicity of intracerebral virus infection depends on anatomical site.

Stevenson PG, Hawke S, Sloan DJ, Bangham CR.

J Virol. 1997 Jan;71(1):145-51.

34.

Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function.

Riemersma S, Vincent A, Beeson D, Newland C, Hawke S, Vernet-der Garabedian B, Eymard B, Newsom-Davis J.

J Clin Invest. 1996 Nov 15;98(10):2358-63.

35.

Protection against lethal influenza virus encephalitis by intranasally primed CD8+ memory T cells.

Stevenson PG, Hawke S, Bangham CR.

J Immunol. 1996 Oct 1;157(7):3065-73.

PMID:
8816416
36.

Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting.

Hawke S, Matsuo H, Nicolle M, Malcherek G, Melms A, Willcox N.

Immunol Today. 1996 Jul;17(7):307-11. Review. No abstract available.

PMID:
8763815
37.

Peptide-selected T cell lines from myasthenia gravis patients and controls recognize epitopes that are not processed from whole acetylcholine receptor.

Matsuo H, Batocchi AP, Hawke S, Nicolle M, Jacobson L, Vincent A, Newsom-Davis J, Willcox N.

J Immunol. 1995 Oct 1;155(7):3683-92.

PMID:
7561069
38.

Differences in processing of an autoantigen by DR4:Dw4.2 and DR4:Dw14.2 antigen-presenting cells.

Nicolle MW, Hawke S, Willcox N, Vincent A.

Eur J Immunol. 1995 Jul;25(7):2119-22.

PMID:
7621887
39.

Detection of alpha-subunit isoforms in human muscle acetylcholine receptor by specific T cells from a myasthenia gravis patient.

Harcourt G, Batocchi AP, Hawke S, Beeson D, Pantic N, Jacobson L, Willcox N, Vincent A, Newsom-Davis J.

Proc Biol Sci. 1993 Oct 22;254(1339):1-6.

PMID:
8265670
40.

Cellular and humoral immunity in patients with insulin-dependent diabetes.

Hawke S, Harcourt G, Pantic N, Beeson D, Willcox N, Newson-Davis J.

Lancet. 1993 Jul 24;342(8865):246. No abstract available.

PMID:
8100970
41.

Stimulation of specific T cells by human AChR adsorbed to immunomagnetic particles.

Hawke S, Willcox N, Harcourt G, Vincent A, Newsom-Davis J.

Ann N Y Acad Sci. 1993 Jun 21;681:288-91. No abstract available.

PMID:
8357171
42.

Differential recognition by T cells of the P3A+ and P3A- isoforms of the human acetylcholine receptor alpha-subunit.

Batocchi AP, Harcourt G, Beeson D, Pantic N, Hawke S, Willcox N, Newsom-Davis J.

Ann N Y Acad Sci. 1993 Jun 21;681:280-2. No abstract available.

PMID:
8357168
43.

Approaches for studying the pathogenic T cells in autoimmune patients.

Willcox N, Baggi F, Batocchi AP, Beeson D, Harcourt G, Hawke S, Jacobson L, Matsuo H, Moody AM, Nagvekar N, et al.

Ann N Y Acad Sci. 1993 Jun 21;681:219-37.

PMID:
8357164
44.

IgG monoclonal paraproteinaemia and peripheral neuropathy.

Bleasel AF, Hawke SH, Pollard JD, McLeod JG.

J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):52-7.

45.

Stimulation of human T cells by sparse antigens captured on immunomagnetic particles.

Hawke S, Willcox N, Harcourt G, Vincent A, Newsom-Davis J.

J Immunol Methods. 1992 Oct 19;155(1):41-8.

PMID:
1383345
46.

T cell responses to human recombinant acetylcholine receptor-alpha subunit in myasthenia gravis and controls.

Sun JB, Harcourt G, Wang ZY, Hawke S, Olsson T, Fredrikson S, Link H.

Eur J Immunol. 1992 Jun;22(6):1553-9.

PMID:
1376263
47.

Vasculitic neuropathy. A clinical and pathological study.

Hawke SH, Davies L, Pamphlett R, Guo YP, Pollard JD, McLeod JG.

Brain. 1991 Oct;114 ( Pt 5):2175-90.

PMID:
1657271
48.
49.

Cranial magnetic resonance imaging in chronic demyelinating polyneuropathy.

Hawke SH, Hallinan JM, McLeod JG.

J Neurol Neurosurg Psychiatry. 1990 Sep;53(9):794-6.

50.

Painful oculomotor nerve palsy due to dural-cavernous sinus shunt.

Hawke SH, Mullie MA, Hoyt WF, Hallinan JM, Halmagyi GM.

Arch Neurol. 1989 Nov;46(11):1252-5.

PMID:
2818263

Supplemental Content

Support Center